In a collaboration between the partner sites Heidelberg and Dresden of the National Center for Tumor Diseases (NCT) a blood extracellular-vesicle-transported mRNA signature to discriminate high risk pancreatic cancers patients and predict overall survival time of the tumor carrying individual was identified. We were fortunate to collaborate.   See the paper published in J Hematol & Oncology.